Inventiva S.A. (IVA) Financial Ratios
12 years of historical data (2013–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 4.83
30Y Low4.1·High6.0
ROE
↓
N/A
—
5yr avg: -454.3%
30Y Low-81%·High-12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IVA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Inventiva S.A. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $200M | $111M | $205M | $185M | $535M | $491M | — | — | — | — | — |
| Enterprise Value | $151M | $69M | $216M | $133M | $459M | $399M | — | — | — | — | — |
| P/E Ratio → | -0.94 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 18.82 | 12.09 | 11.73 | 15.18 | 127.57 | 1320.39 | — | — | — | — | — |
| P/B Ratio | — | — | — | 4.07 | 6.02 | 4.42 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IVA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.50 | 12.33 | 10.89 | 109.35 | 1071.91 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
IVA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Inventiva S.A. earns an operating margin of -1060.6%. Operating margins have compressed from -468.9% to -1060.6% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.1% | 140.1% | 100.0% | 1187.4% | 100.0% | 69.8% | 81.0% | 84.3% | 71.2% |
| Operating Margin | -1060.6% | -1060.6% | -587.7% | -468.9% | -1242.6% | -7988.7% | -433.2% | -1040.1% | -320.8% | -137.8% | -318.2% |
| Net Profit Margin | -2002.7% | -2002.7% | -631.8% | -445.6% | -1183.5% | -9037.4% | -431.9% | -1051.5% | -264.2% | -74.6% | -181.0% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -1642.8% | -80.8% | -49.6% | -44.1% | -58.7% | -53.5% | -34.6% | -18.0% | -18.7% |
| ROA | -195.4% | -195.4% | -119.0% | -45.6% | -38.0% | -34.3% | -44.2% | -43.6% | -28.0% | -12.9% | -13.2% |
| ROIC | — | — | — | -1506.6% | -279.0% | -209.8% | -356.0% | -397.5% | -185.4% | -60.4% | -42.0% |
| ROCE | -1106.2% | -1106.2% | -196.2% | -61.9% | -46.5% | -35.4% | -56.2% | -51.0% | -39.5% | -28.0% | -25.8% |
IVA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $97M exceeds total debt of $54M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.76 | 0.11 | 0.09 | 0.00 | 0.04 | 0.01 | 0.02 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | -1.15 | -0.86 | -0.83 | -0.86 | -0.88 | -0.92 | -0.68 | -0.51 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.01 | -8.01 | -19.84 | -80.78 | -377.64 | -450.27 | -10104.00 | -136.83 | -3934.53 | -1724.82 | -2558.97 |
Net cash position: cash ($97M) exceeds total debt ($54M)
IVA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.92x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 3.47x to 0.92x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.92 | 0.92 | 0.96 | 3.47 | 5.06 | 9.56 | 3.53 | 4.75 | 7.64 | 4.80 | 3.69 |
| Quick Ratio | 0.92 | 0.92 | 0.95 | 3.45 | 5.04 | 9.54 | 3.50 | 4.72 | 7.59 | 4.74 | 3.63 |
| Cash Ratio | 0.80 | 0.80 | 0.54 | 2.86 | 3.79 | 8.13 | 2.58 | 3.76 | 6.71 | 2.89 | 2.92 |
| Asset Turnover | — | 0.08 | 0.25 | 0.10 | 0.03 | 0.00 | 0.12 | 0.04 | 0.09 | 0.19 | 0.08 |
| Inventory Turnover | -0.06 | — | -0.06 | 2.67 | — | 2.64 | — | 2.36 | 2.61 | 3.15 | 2.92 |
| Days Sales Outstanding | — | 482.42 | 328.03 | 8.36 | 1008.41 | 47.10 | 33.54 | 1520.28 | 383.99 | 173.97 | 73.88 |
IVA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Inventiva S.A. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $52M | $45M | $41M | $39M | $34M | $24M | $21M | $16M | $16M | $10M |
Peer Comparison
Compare IVA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IVAYou | $200M | -0.9 | — | — | 100.0% | -1060.6% | — | — | — |
 MDGL | $11B | -37.4 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 AKBA | $248M | -44.4 | 11.3 | 3.6 | 83.3% | 9.9% | -16.4% | 23.2% | 8.7 |
 HALO | $8B | 27.1 | 11.3 | 12.8 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 CLDX | $2B | -8.0 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 GNFT | $448M | 256.9 | 73.1 | 27.1 | 99.6% | 4.9% | 2.2% | 4.5% | 12.4 |
 VKTX | $3B | -9.0 | — | — | — | — | -47.3% | -44.4% | — |
 ARWR | $10B | -6108.2 | 87.0 | 66.9 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 ALDX | $106M | -3.1 | — | — | — | — | -58.7% | -245.8% | — |
 AZN | $277B | 27.3 | 15.5 | 23.6 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 NVS | $292B | 21.3 | 14.2 | 16.5 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
What if you invested $1,000 in IVA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in IVA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs IVA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationIVA vs MDGL — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Madrigal Pharmaceuticals, Inc..
Compare NowIVA — Frequently Asked Questions
Quick answers to the most common questions about buying IVA stock.
What is Inventiva S.A.'s P/E ratio?
Inventiva S.A.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
Is IVA stock overvalued?
Based on historical data, Inventiva S.A. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Inventiva S.A.'s profit margins?
Inventiva S.A. has 100.0% gross margin and -1060.6% operating margin.